Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma
Abstract Background Localised renal cell carcinoma (RCC) is usually treated surgically, with post‐operative imaging‐based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients often lack a clear understanding of their risk of recurrence and follow‐up care....
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.70014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172965914673152 |
|---|---|
| author | Panayiotis Laouris Chiara Re Georgia Stimpson Axel Bex James Blackmur Alexander Laird Carley Batley Grant D. Stewart Hannah Harrison Juliet A. Usher‐Smith |
| author_facet | Panayiotis Laouris Chiara Re Georgia Stimpson Axel Bex James Blackmur Alexander Laird Carley Batley Grant D. Stewart Hannah Harrison Juliet A. Usher‐Smith |
| author_sort | Panayiotis Laouris |
| collection | DOAJ |
| description | Abstract Background Localised renal cell carcinoma (RCC) is usually treated surgically, with post‐operative imaging‐based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients often lack a clear understanding of their risk of recurrence and follow‐up care. The PREDICT Kidney tool has been developed to enhance risk communication by providing individualised recurrence and mortality risk estimates. The tool uses the Leibovich score augmented with English national data to provide a personalised risk assessment of cancer recurrence and death from other causes, presented in both numerical and visual formats. Study Design A multicentre, prospective feasibility study of incorporating the PREDICT Kidney risk communication tool into the first follow‐up consultation for localised RCC patients post‐surgery. Endpoints Patient uptake into the study, completeness of data collection, consultation duration, the acceptability of the tool to both patients and clinicians, clinician adherence to the study “best‐practice” guide, variability in tool usage across clinicians and sites and patient‐level clinical outcomes including subjective and objective comprehension of risk of recurrence and follow‐up, perceived risk of cancer recurrence, risk conviction, satisfaction with the information provided on risk of recurrence and follow‐up, and fear of cancer recurrence. Patients and Methods We aim to recruit 60 patients from three hospitals in England and Scotland. Patients treated with surgery for primary localised clear‐cell RCC awaiting their first follow‐up appointment will be invited to take part. Participants will be allocated into two groups: standard care and standard care supplemented with the use of the PREDICT Kidney tool. Data will be collected through questionnaires, audio/video recordings of consultations and interviews with a subset of patients and clinicians. The study period is planned from September 2024 to July 2025. The findings will guide the design of a future randomised controlled trial to evaluate the tool's efficacy in clinical settings. |
| format | Article |
| id | doaj-art-3668dbcdf329463db584ece1a5e5b0b4 |
| institution | OA Journals |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-3668dbcdf329463db584ece1a5e5b0b42025-08-20T02:19:57ZengWileyBJUI Compass2688-45262025-04-0164n/an/a10.1002/bco2.70014Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinomaPanayiotis Laouris0Chiara Re1Georgia Stimpson2Axel Bex3James Blackmur4Alexander Laird5Carley Batley6Grant D. Stewart7Hannah Harrison8Juliet A. Usher‐Smith9Department of Public Health and Primary Care University of Cambridge Cambridge UKDepartment of Surgery University of Cambridge, Addenbrooke's Hospital Cambridge UKDepartment of Public Health and Primary Care University of Cambridge Cambridge UKRoyal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science London UKWestern General Hospital, NHS Lothian Edinburgh UKWestern General Hospital, NHS Lothian Edinburgh UKDepartment of Oncology University of Cambridge, Addenbrooke's Hospital Cambridge UKDepartment of Surgery University of Cambridge, Addenbrooke's Hospital Cambridge UKDepartment of Public Health and Primary Care University of Cambridge Cambridge UKDepartment of Public Health and Primary Care University of Cambridge Cambridge UKAbstract Background Localised renal cell carcinoma (RCC) is usually treated surgically, with post‐operative imaging‐based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients often lack a clear understanding of their risk of recurrence and follow‐up care. The PREDICT Kidney tool has been developed to enhance risk communication by providing individualised recurrence and mortality risk estimates. The tool uses the Leibovich score augmented with English national data to provide a personalised risk assessment of cancer recurrence and death from other causes, presented in both numerical and visual formats. Study Design A multicentre, prospective feasibility study of incorporating the PREDICT Kidney risk communication tool into the first follow‐up consultation for localised RCC patients post‐surgery. Endpoints Patient uptake into the study, completeness of data collection, consultation duration, the acceptability of the tool to both patients and clinicians, clinician adherence to the study “best‐practice” guide, variability in tool usage across clinicians and sites and patient‐level clinical outcomes including subjective and objective comprehension of risk of recurrence and follow‐up, perceived risk of cancer recurrence, risk conviction, satisfaction with the information provided on risk of recurrence and follow‐up, and fear of cancer recurrence. Patients and Methods We aim to recruit 60 patients from three hospitals in England and Scotland. Patients treated with surgery for primary localised clear‐cell RCC awaiting their first follow‐up appointment will be invited to take part. Participants will be allocated into two groups: standard care and standard care supplemented with the use of the PREDICT Kidney tool. Data will be collected through questionnaires, audio/video recordings of consultations and interviews with a subset of patients and clinicians. The study period is planned from September 2024 to July 2025. The findings will guide the design of a future randomised controlled trial to evaluate the tool's efficacy in clinical settings.https://doi.org/10.1002/bco2.70014feasibility trialkidney cancerrecurrence risksrisk communicationrisk estimates |
| spellingShingle | Panayiotis Laouris Chiara Re Georgia Stimpson Axel Bex James Blackmur Alexander Laird Carley Batley Grant D. Stewart Hannah Harrison Juliet A. Usher‐Smith Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma BJUI Compass feasibility trial kidney cancer recurrence risks risk communication risk estimates |
| title | Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma |
| title_full | Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma |
| title_fullStr | Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma |
| title_full_unstemmed | Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma |
| title_short | Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma |
| title_sort | feasibility study of using the predict kidney tool for patients with localised renal cell carcinoma |
| topic | feasibility trial kidney cancer recurrence risks risk communication risk estimates |
| url | https://doi.org/10.1002/bco2.70014 |
| work_keys_str_mv | AT panayiotislaouris feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT chiarare feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT georgiastimpson feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT axelbex feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT jamesblackmur feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT alexanderlaird feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT carleybatley feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT grantdstewart feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT hannahharrison feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma AT julietaushersmith feasibilitystudyofusingthepredictkidneytoolforpatientswithlocalisedrenalcellcarcinoma |